Chemical Namesofosbuvir
Dosage FormTablet (oral; 200 mg, 400 mg); Pellets (oral; 150 mg, 200 mg)
Drug ClassAntivirals
CompanyGilead Sciences
Approval Year2013


  • For the treatment of adult patients with genotype 1, 2, 3 or 4 chronic HCV infection without cirrhosis or with compensated cirrhosis as a component of a combination antiviral treatment regimen.
  • For the treatment of pediatric patients 3 years of age and older with genotype 2 or 3 chronic HCV infection without cirrhosis or with compensated cirrhosis in combination with ribavirin.
Last updated on 6/22/2022

More on this drug: Clinical Trials

Document TitleYearSource
Sovaldi (sofosbuvir) Prescribing Information.2020Gilead Sciences, Inc., Foster City, CA
Document TitleYearSource
Real-world effectiveness of direct-acting antiviral regimens against hepatitis C virus (HCV) genotype 3 infection: a systematic review and meta-analysis.2021Annals of Hepatology
Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta‑analysis.2020Scientific Reports
Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co‐infection: systematic review and network meta‐analysis. 2020Journal of Gastroenterology and Hepatology
An updated systematic review and metaanalysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease.2020PLoS One
Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4–5 chronic kidney disease: a systematic review and meta-analysis.2019Virology Journal
Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: a systematic review and meta-analysis. 2019Journal of Hepatology
Systematic review with meta‐analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma.2019Alimentary Pharmacology and Therapeutics
A systematic review with meta-analysis: Is ribavirin necessary in sofosbuvir-based direct-acting antiviral therapies for patients with HCV recurrence after liver transplantation?2019International Journal of Infectious Diseases
Cardiac harms of sofosbuvir: Systematic review and meta-analysis. 2018Drug Safety
Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis.2018BMJ Open Gastroenterology
Direct‐acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta‐analysis.2018Transplant Infectious Disease
The Efficacy and Safety of 12 Weeks of sofosbuvir and ledipasvir versus sofosbuvir, ledipasvir, and ribavirin in patients with chronic hepatitis C, genotype 1, who have cirrhosis and have failed prior therapy: A systematic review and meta-analysis.2017Canadian Journal of Gastroenterology and Hepatology
Combination of sofosbuvir, pegylatedinterferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis.2017Daru
Direct-acting antivirals for chronic hepatitis C.2017Cochrane Database of Systematic Reviews
Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review.2017BMC Infectious Diseases
Identification of the best direct-acting antiviral regimen for patients with hepatitis C virus genotype 3 infection: a systematic review and network meta-analysis.2017Clinical Gastroenterology and Hepatology
Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis. 2017Alimentary Pharmacology and Therapeutics
Document TitleYearSource
HCV Guidance: recommendations for testing, managing, and treating Hepatitis C.2021American Association for the Study of Liver Diseases
EASL recommendations on treatment of hepatitis C: final update of the series.2020Journal of Hepatology

Have we missed a study, or would you like to comment on a study?